Long-term thionamide antithyroid treatment of Graves' disease.

Abstract

Thionamide antithyroid drugs (ATD) are the treatment of choice for Graves' hyperthyroidism. The major drawback of ATD treatment for 1-2 years is the relapse of hyperthyroidism in about 50% of patients. Recently, it has been shown that ATD treatment for more than five years is accompanied by long-term remission in majority of patients without additional major side effects in both adults and children. Compared to radioactive iodine therapy, long-term ATD results in more favorable outcomes. This review summarizes the evidence on long-term ATD therapy regarding the remission rate of hyperthyroidism, efficacy and safety, indications and mode of therapy in patients with hyperthyroidism.

• Authors: Fereidoun Azizi, Hengameh Abdi, Atieh Amouzegar, Ali Siamak Habibi Moeini
• Journal: Best practice & research. Clinical endocrinology & metabolism (Best Pract Res Clin Endocrinol Metab) Vol. 37 Issue 2 Pg. 101631 (03 2023) ISSN: 1878-1594 [Electronic] Netherlands
• PMID: 35440398 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022. Published by Elsevier Ltd.

Chemical References

• Methimazole
• Iodine Radioisotopes
• Antithyroid Agents

Topics

• Adult
• Child
• Humans
• Methimazole (adverse effects)
• Iodine Radioisotopes (therapeutic use)
• Treatment Outcome
• Thyroid Neoplasms (drug therapy)
• Neoplasm Recurrence, Local
• Graves Disease (drug therapy, radiotherapy)
• Antithyroid Agents (adverse effects)
• Hyperthyroidism (drug therapy)